Current Treatment Options in Oncology

, Volume 13, Issue 3, pp 377–389 | Cite as

Targeted Therapy for Gastric Cancer

Gastrointestinal Cancers (AB Benson, Section Editor)

Opinion statement

For patients with advanced gastric cancer, traditional double or triplet cytotoxic chemotherapy regimens result in a median survival of 9–11 months. As combination therapy is associated with increased survival, but also increased toxicity in a patient population whose performance status often compromised by their malignancy, development of more effective and less toxic treatment choices is mandated. Emerging data from gene expression profiling suggests that differences in pathological appearance and clinical behavior may be due the presence of unique molecular phenotypes. Characterization of the gastric cancer genomic landscape reveals the presence of multiple alterations in expression of receptor tyrosine kinases, which in conjunction with their ligands and downstream effector molecules represent potentially druggable pathways for future drug development. Treatment of HER2 positive gastric cancer with trastuzumab has led to significant gains in overall survival, and further manipulation of this pathway using the novel anti-HER2 directed agents pertuzumab and T-DM1 in addition to dual EGFR/HER2 blockade with lapatinib may yield positive results. In contrast, targeting of the EGFR pathway in combination with chemotherapy in unselected patients has not been fruitful to date, with no significant gains over standard chemotherapy yet demonstrated. Similarly, use of the anti-angiogenic monoclonal antibody bevacizumab was not successful in a large global randomized trial; however intriguing regional variations were seen with respect to efficacy of this drug, leading to calls for a second, regionally stratified study. Careful selection of patient subsets will become a key factor in future clinical trials, as novel targeted agents such as those targeting the MET/HGF and FGFR axes move forward into clinical development. It is hoped that treatment of patients in such molecularly defined groups is will lead to significant gains in survival compared to current treatment paradigms.

Keywords

Gastric cancer Targeted therapy Molecular classification HER2 EGFR Trastuzumab Bevacizumab FGFR MET 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med. 2006;355(1):11–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl J Med. 2001;345(10):725–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New Engl J Med. 2008;358(1):36–46.PubMedCrossRefGoogle Scholar
  4. 4.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Wagner AD, Unverzagt S, GrotheW, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010;(3): p. CD004064.Google Scholar
  6. 6.
    Wu H, Rusiecki JA, Zhu K, et al. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009;18(7):1945–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010;8(4):437–47.PubMedGoogle Scholar
  8. 8.••
    Tan IB, Ivanova T, KH Lim, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011;141(2):476–485.e11.PubMedCrossRefGoogle Scholar
  9. 9.
    Shah MA, Khanin R, Tang L, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17(9):2693–701.PubMedCrossRefGoogle Scholar
  10. 10.•
    Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012. Comprehensive review of genomic landscape of gastric cancer.Google Scholar
  11. 11.
    Corso G, Velho S, Paredes J, et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer. 2011;47(3):443–51.PubMedCrossRefGoogle Scholar
  12. 12.••
    Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRefGoogle Scholar
  13. 13.
    Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New Engl J Med. 2012;366(2):109–19.PubMedCrossRefGoogle Scholar
  14. 14.
    Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)—positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398–405.PubMedCrossRefGoogle Scholar
  15. 15.
    Iqbal S, Goldman B, Fenoglio-Preiser CM, et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Annals of Oncology 2011.Google Scholar
  16. 16.
    Hecht J, Urba G, Koehler M, Ellis C. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. Proc GI ASCO 2008;43(abstr 43).Google Scholar
  17. 17.
    Pishvaian M, Sakaeva D, Hsieh RK. A global, multicenter phase II trial of lapatinib plus capecitabine in gastric cancer. J Clin Oncol 2011;29(suppl 4; abstr 88).Google Scholar
  18. 18.
    Kim MA, Lee HS, Lee HE, et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008;52(6):738–46.PubMedCrossRefGoogle Scholar
  19. 19.
    Ilson DH, Kelsen D, Shah M, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 2011;117(7):1409–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006;24(30):4922–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol. 2006;24(10):1612–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res. 2007;13(19):5869–75.PubMedCrossRefGoogle Scholar
  23. 23.
    Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011;22(6):1367–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;101(8):1261–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18(3):510–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Annals of Oncology 2010.Google Scholar
  27. 27.
    Kim C, Lee J-L, Ryu M-H, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs. 2011;29(2):366–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer. 2009;100(2):298–304.PubMedCrossRefGoogle Scholar
  29. 29.
    Enzinger P, Burtness B, Hollis D, Niedzwiecki D, Ilson D. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010;28(15s):p. abstr 4006.Google Scholar
  30. 30.
    Richards DA, Kocs DM, Spira AI. Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma: Results of a randomized phase II study. J Clin Oncol 2011;29(suppl; abstr 4015).Google Scholar
  31. 31.
    Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol. 2010;21(11):2213–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Okines AFC, Ashley SE, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol. 2010;28(25):3945–50.PubMedCrossRefGoogle Scholar
  33. 33.
    Luber B, Deplazes J, Keller G, et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer. 2011;11:509.PubMedCrossRefGoogle Scholar
  34. 34.
    Pinto C, Mutri V, Di Fabi F. Analysis of biomarker expression (ki67, EGFR, HER2, ERK, NFkB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study. J Clin Oncol 2010. 28(suppl; abstr 4133).Google Scholar
  35. 35.
    Vidal Ó, Metges JP, Elizalde I, et al. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg. 2009;96(12):1443–51.PubMedCrossRefGoogle Scholar
  36. 36.
    Chen J, Li T, Wu Y, et al. Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2011;137(12):1799–812.PubMedCrossRefGoogle Scholar
  37. 37.
    Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011;29(7):868–74.PubMedCrossRefGoogle Scholar
  38. 38.
    Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24(33):5201–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Enzinger P, Ryan D, Regan E. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. JCO 2008;26(4552):p. abstr 97.Google Scholar
  40. 40.
    El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol. 2010;21(10):1999–2004.PubMedCrossRefGoogle Scholar
  41. 41.••
    Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76.PubMedCrossRefGoogle Scholar
  42. 42.
    Okines A, Langley R, Cafferty F, et al. Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma. J Clin Oncol 2010;28 (15 suppl:4019).Google Scholar
  43. 43.
    Ilson D, Janjigian Y, Shah M. Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma. J Clin Oncol 2011;29(suppl 4; abstr 41).Google Scholar
  44. 44.
    Kim C, Lee J-L, Choi Y, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs. 2012;30(1):306–15.PubMedCrossRefGoogle Scholar
  45. 45.
    Sun W, Powell M, O’Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010;28(18):2947–51.PubMedCrossRefGoogle Scholar
  46. 46.
    Moehler M, Mueller A, Hartmann JT, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer. 2011;47(10):1511–20.PubMedCrossRefGoogle Scholar
  47. 47.
    Bang Y-J, Kang Y-K, Kang W, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investigational New Drugs 2010; p. 1–10.Google Scholar
  48. 48.
    Al-Batran S-E, Ducreux M, Ohtsu A. mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer. 2012;130(3):491–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol. 2010;28(11):1904–10.PubMedCrossRefGoogle Scholar
  50. 50.
    Yoon DH, Ryu MH, Park YS, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer. 2012;106(6):1039–44.PubMedCrossRefGoogle Scholar
  51. 51.
    Van Cutsem E, Yeh K, Bang Y. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 2012;30(suppl 4; abstr LBA3).Google Scholar
  52. 52.
    Graziano F, Galluccio N, Lorenzini P, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 2011;29(36):4789–95.PubMedCrossRefGoogle Scholar
  53. 53.
    Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29(36):4803–10.PubMedCrossRefGoogle Scholar
  54. 54.
    Jhawer MKH, Wainberg Z, Ford F. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol 2009;27(15s):p. (suppl; abstr 4502)Google Scholar
  55. 55.
    Iveson T, Donehower I, DAvidenco S. Safety and Efficacy of Epirubicin, Cisplatin and Capecitabine (ECX) plus rilotumumab as first line treatment for unresectable locally advanced or metastatic gastric or esophagogastric junction carcinoma, in ECCO 2011: Stockholm.Google Scholar
  56. 56.
    Catenacci DVT, Henderson L, Xiao S-Y, et al. Durable complete response of metastatic gastric cancer with anti-met therapy followed by resistance at recurrence. Cancer Discovery. 2011;1(7):573–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Gavine PR, Mooney L, Kilgour E, et al. AZD4547: An orally bioavailable, potent and selective inhibitor of the Fibroblast Growth Factor Receptor tyrosine kinase family. Cancer Research 2012.Google Scholar
  58. 58.
    Takeda M, Arao T, Yokote H, et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res. 2007;13(10):3051–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Ratain M, Schwartz G, Orza A. Brivanib (BMS-582664) in advanced solid tumors (AST): results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2011;29(suppl; abstr 3079).Google Scholar
  60. 60.
    Woll E, Greil R, Eisterer W, et al. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT). Anticancer Res. 2011;31(12):4439–43.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Royal Marsden HospitalSurreyUK

Personalised recommendations